RC48 Monotherapy or Combination With Envafolimab for CDK12 Alterations mCRPC With Standard Treatment Failure

The aim of this study is to evaluate the efficacy and safety of vediximab monotherapy or in combination with enrolizumab for second-line treatment of CDK12 alterations mCRPC that has failed standard therapy. The research results are expected to provide new insights and breakthroughs for the treatment of advanced prostate cancer.

NCT Number	NCT06663007
Lead Sponsor	Tianjin Medical University Second Hospital
Conditions	Prostate Cancer, CDK12 Gene Mutation
Enrollment	72 participants
Start Date	2024-09-24
Primary Completion	2027-05-31 (estimated)
Study Completion	2027-08-31 (estimated)
Updated on ClinicalTrials.gov	2024-10-29